American Ginseng

A randomized, double-blind, placebo-controlled crossover trial demonstrated that American ginseng (Panax quinquefolius 1g twice daily for 4 weeks) significantly reduced warfarin peak INR and warfarin area-under-the-INR-curve versus placebo. Ginsenosides from American ginseng may induce CYP2C9 activity (responsible for S-warfarin metabolism) or independently affect clotting factor synthesis, reducing anticoagulant efficacy.

Monitor INR closely when American ginseng is started or stopped in patients on warfarin. Patients may require warfarin dose increases to maintain therapeutic anticoagulation. Ideally, avoid this combination in patients dependent on stable anticoagulation (atrial fibrillation, mechanical heart valves, DVT/PE prophylaxis).

Multiple controlled clinical trials have demonstrated that American ginseng (3g taken 40 minutes before meals) significantly reduces post-prandial blood glucose and improves insulin sensitivity. When combined with antidiabetic medications, additive hypoglycemic effects may result in hypoglycemia, especially with insulin or sulfonylureas.

Monitor blood glucose carefully when combining American ginseng with antidiabetic drugs. Counsel patients on hypoglycemia symptoms (diaphoresis, tremor, confusion, tachycardia). Dose reduction of antidiabetic agents may be warranted. Time ginseng intake consistently relative to meals.

American ginseng polysaccharides and ginsenosides stimulate NK cell activity, T-lymphocyte proliferation, and macrophage activation. These immunostimulatory properties may antagonise immunosuppressant medications in transplant recipients, increasing rejection risk. Ginsenoside-mediated P-glycoprotein inhibition may also alter cyclosporine/tacrolimus pharmacokinetics.

Avoid use in solid organ transplant patients receiving immunosuppression. If used, monitor drug trough levels (cyclosporine, tacrolimus) and transplant function closely. Immunostimulation may compromise graft tolerance.

Ginsenosides possess mild stimulant and monoamine-modulating properties. Case reports exist of manic-like symptoms, insomnia, and agitation when ginseng species are combined with MAO inhibitors (reported for P. ginseng; applicable by class effect to P. quinquefolius). Combined MAOI activity plus ginsenoside stimulation may increase hypertensive crisis and serotonin toxicity risk.

Avoid concurrent use of American ginseng with MAO inhibitors. Monitor for signs of MAOI-related toxicity (hypertensive crisis, agitation, tachycardia, hyperthermia). Washout period of at least 14 days recommended after stopping MAOIs.

A pharmacokinetic study in healthy volunteers using fexofenadine as a P-glycoprotein probe demonstrated weak P-gp inhibition by Panax ginseng products. Similar effects may apply to American ginseng, potentially increasing plasma concentrations of P-gp substrates (digoxin, dabigatran) due to reduced intestinal efflux.

Monitor serum levels of narrow therapeutic index P-gp substrates (digoxin) when American ginseng is introduced. Check digoxin levels and watch for toxicity signs (nausea, bradycardia, visual disturbances). Exercise caution with dabigatran in patients at risk of bleeding.

A clinical pharmacokinetic study in 14 healthy volunteers demonstrated that American ginseng (Panax quinquefolius 2g three times daily for 2 weeks) significantly increased indinavir AUC and Cmax, possibly via inhibition of CYP3A4-mediated intestinal first-pass metabolism or P-glycoprotein-mediated efflux, potentially increasing indinavir toxicity (nephrolithiasis, hyperbilirubinemia, GI effects).

Avoid combining American ginseng with HIV protease inhibitors. If unavoidable, monitor for protease inhibitor toxicity (hyperbilirubinemia, kidney stones, GI adverse effects). Inform the HIV prescribing physician of supplement use.